DiaMedica Therapeutics, Inc.

As of May 9, 2025, DiaMedica Therapeutics, Inc. shows a mildly bearish trend, with weekly indicators suggesting bearish conditions, while monthly metrics indicate some underlying strength, resulting in an overall bearish outlook.

As of March 2022, the management team of DiaMedica Therapeutics, Inc. includes Mr. Richard Pilnik (Independent Chairman), Mr. Rick Pauls (President and CEO), Dr. Harry Alcorn, Mr. James Parsons, Dr. Jerry Xiao, and Dr. Michael Giuffre (Independent Director). They oversee the company's strategic direction and operations.

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing recombinant proteins for kidney and neurological diseases, with a market cap of approximately $153.09 million. As of March 2025, the company reported a net profit loss of $8 million.

As of Jun 18, DiaMedica Therapeutics, Inc. has a market capitalization of 153.09 million, with net sales of 0.00 million and a net profit of -27.00 million over the latest four quarters. Shareholder's funds are 40.72 million and total assets are 46.34 million as of Dec 24.